Trial Profile
A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranasal Dose (Versus Placebo) in Healthy Adult Volunteers who are Subsequently Challenged with a Live, Antigenically Different Wild-type Influenza Type A Virus (A/Belgium/4217/2015 H3N2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2021
Price :
$35
*
At a glance
- Drugs H3N2 M2SR influenza vaccine-FluGen (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors FluGen
- 02 Aug 2021 According to a FluGen media release, results published in the Journal of Infectious Diseases.
- 02 Aug 2021 Results published in FluGen Media Release.
- 29 Jul 2021 Primary endpoint has been met. (Area under the curve (AUC) of the influenza RNA log10 viral load by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) from nasopharyngeal swabs of study subjects), as per published in the Journal of Infectious Diseases